SCHEMBL6375083

SCHEMBL6375083

O=C(O)CSCc1c(Cl)cccc1Cl

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.78
HTT P42858 1/20 0.65
KMT2A Q03164 1/20 0.65
ALDH1A1 P00352 6/20 0.59
HPGD P15428 5/20 0.59
POLB P06746 1/20 0.59
AKR1B1 P15121 1/20 0.57
L3MBTL1 Q9Y468 3/20 0.55
LMNA P02545 2/20 0.55
NPY1R P25929 1/20 0.55
NPY2R P49146 1/20 0.55
GAA P10253 1/20 0.54
TP53 P04637 1/20 0.53
MAPT P10636 1/20 0.52
RECQL P46063 1/20 0.51
CYP1A2 P05177 2/20 0.49
FABP3 P05413 1/20 0.49
FABP4 P15090 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3743740 0.85 KMT2A (0.65) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL11271730 0.80 KMT2A (0.73) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL9456771 0.79 HTT (0.55) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL11271689 0.78 HTT (0.65) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL8188333 0.77 KDM4E (0.78) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL8183584 0.77 KDM4E (0.54) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL20846607 0.74 GAA (0.63) HTTKMT2AALDH1A1HPGDPOLB
SCHEMBL3142048 0.74 KDM4E (0.77) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL11871475 0.74 KIF11 (0.49) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL11871473 0.74 KIF11 (0.49) KDM4EHTTKMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1003497-B1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2005-08-31 EP disclosed
EP-1003509-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-11-20 EP disclosed
EP-1003497-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-11-13 EP disclosed
EP-1039903-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2001-12-05 EP disclosed
US-6316478-B1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2001-11-13 US disclosed
US-6297265-B2 UREAS OR THIOUREAS SMITHKLINE BEECHAM CORPORATION 2001-10-02 US disclosed
US-20010018447-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION 2001-08-30 US disclosed
EP-1039903-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-10-04 EP disclosed
EP-1003509-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-05-31 EP disclosed
EP-1003497-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-05-31 EP disclosed
WO-1999011264-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-03-11 WO disclosed
WO-1999011253-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-03-11 WO disclosed
US-4325964-A SEDATIVES, MUSCLE RELAXANTS, HYPOTENSIVE AGENTS LABORATOIRE L. LAFON (FR) 1982-04-20 US disclosed
US-4225617-A PSYCHOTROPIC AGENTS LABORATOIRE L. LAFON (FR) 1980-09-30 US disclosed
US-4209524-A CENTRAL NERVOUS SYSTEM LABORATOIRE L. LAFON (FR) 1980-06-24 US disclosed
US-4209523-A TREATMENT OF THE CENTRAL NERVOUS SYSTEM LABORATOIRE L. LAFON (FR) 1980-06-24 US disclosed
US-4183951-A PSYCHOTROPIC AGENTS LABORATOIRE L. LAFON (FR) 1980-01-15 US disclosed
US-4152458-A CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC AGENTS LABORATOIRE L. LAFON (FR) 1979-05-01 US disclosed
US-4151300-A CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC LABORATOIRE L. LAFON (FR) 1979-04-24 US disclosed
US-4122186-A PSYCHOTROPIC AGENTS LABORATOIRE L. LAFON (FR) 1978-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018447-A1 IL-8 RECEPTOR ANTAGONISTS CXCL8, CCR8, IL5 KDM4E 4049/4885HTT 3532/4885KMT2A 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.